Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
Rejuvenation Water is a worlds first amino-acid enriched spring water that brings amino-acids to you in a convenient, healthy and tasty day. In 2016, Rejuvenation Water have opened up over 150 retail listings and have agreed a listing with Holland & Barrett.
days to go:
Expired
investment:
£187,340
Pynk is a fintech that is doing things differently—it relies on Artificial Intelligence, crowd wisdom and expert analysis to boost social investing, allowing its users commission-free investing. Users on the Pynk platform make short term price predictions and long term forecasts on financial assets. Pynk then aggregates the data and runs it through its 'Rose' AI and experts team to give accurate trading and investment analyses. The platform has more than 27,000 users from over 180 countries. Pynk also won the 'Best AI' startups award at the AIBC Blockchain Summit in Malta. It is also a part of the London fintech accelerator programmes with National Westminster and Royal Bank of Scotland. The company will use the investment to launch a retail investor wallet in the 4th quarter of 2020, recruit £10 million Assets Under Management (AUM) by end of 2020, and build out its team across different verticals.
days to go:
Expired
investment:
£574,550
Driftrock are a digitasl media media marketing company who specialise in creating simple easy to use advertising tools.
days to go:
Expired
investment:
£800,278
B-North is a UK-based business lending company. It has combined cloud-native technology with face-to-face relationship banking. The company asserts that SMEs account for over 60% of private-sector employment in the UK, have driven job growth over the past ten years, and are central to driving economic recovery. It intends to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. B-North has raised a seed capital of over £6.8 million including a six-figure investment from the Greater Manchester Combined Authority to establish its core team, as well as, build lending and deposit-taking platforms. The company is now seeking further investment through a bridge round to extend the cash runway from the end of Q4 2020 into Q1-Q2 2021 to achieve the necessary regulatory capital to become a bank and commence lending.
days to go:
Expired
investment:
£2,149,256
